Our experiments revealed that the intrathecal injection of an anti-LFA-1 antibody after the onset of EAE has a significant impact on disease progression, suggesting that interfering with the motility of activated T cells in the CNS could offer a new approach for the treatment of autoimmune diseases such as MS. The gene discussed is ITGAL; the disease is autoimmune disease.